Xeris Pharmaceuticals Inc. (XERS) Tops Q2 EPS by 3c

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q2 EPS of ($0.19), $0.03 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $25.3 million versus the consensus estimate of $26.1 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2022 revenue of $105-120 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• First Industrial Realty (FR) Tops Q1 EPS by 21c
• Triumph Financial, Inc. (TFIN) Misses Q1 EPS by 20c
• Old Second Bancorp (OSBC) Reports In-Line Q1 EPS